{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:09:52Z","timestamp":1788174592481,"version":"build-2803163510"},"reference-count":33,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Marginal zone lymphoma (MZL) is a group of indolent B-cell malignancies with a remitting and relapsing course. For systemic disease, available first-line therapies include anti-CD20 antibody as monotherapy or in combination with chemotherapy (chemoimmunotherapy), with second-line options including covalent Bruton tyrosine kinase inhibitors (cBTKi). However, management of relapsed and refractory (R\/R) MZL remains challenging. Pirtobrutinib, a highly selective, noncovalent BTKi has shown promising efficacy and tolerability in poor-prognosis B-cell malignancies following prior therapy, including cBTKi. Here, we report the safety and efficacy of pirtobrutinib in MZL from the phase 1\/2 BRUIN study. Endpoints included investigator-assessed objective response rate (ORR) by Lugano 2014 criteria, duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. Among 36 patients with R\/R MZL (extranodal [n = 6]; nodal [n = 17]; splenic [n = 13]), median age was 68 years (range, 22-83) and median prior lines of therapy were 3 (range, 2-10). The ORR was 55.6% (95% confidence interval [CI], 38.1- 72.1), including 3 (8.3%) complete responses and 17 (47.2%) partial responses. Median DOR was 17.8 months (95% CI, 7.4 to nonestimable [NE]), and median PFS was 16.6 months (95% CI, 9.0-22.1). With median follow-up of 32.4 months (IQR, 28.0-41.3), median OS was NE (95% CI, 29.5-NE). The ORR for patients with prior cBTKi therapy was 53.8% (95% CI, 33.4-73.4). Pirtobrutinib was well tolerated with dose reductions in 4 patients (11.1%) and permanent discontinuation due to treatment emergent adverse events in 4 patients (11.1%). Pirtobrutinib showed promising efficacy and safety in patients with heavily pretreated R\/R MZL, including prior cBTKi. This trial was registered at www.clinicaltrials.gov as #NCT03740529.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017489","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T20:07:08Z","timestamp":1768594028000},"page":"2441-2451","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R\/R marginal zone lymphoma: phase 1\/2 BRUIN study"],"prefix":"10.1182","volume":"10","author":[{"given":"Krish","family":"Patel","sequence":"first","affiliation":[{"name":"1Swedish Cancer Institute, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1015-7434","authenticated-orcid":false,"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[{"name":"2Division of Hematology, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita D.","family":"Nasta","sequence":"additional","affiliation":[{"name":"3Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-4961","authenticated-orcid":false,"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[{"name":"4Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kami J.","family":"Maddocks","sequence":"additional","affiliation":[{"name":"5The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-9144","authenticated-orcid":false,"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[{"name":"5The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4336-1071","authenticated-orcid":false,"given":"Nirav N.","family":"Shah","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Oncology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2124-7243","authenticated-orcid":false,"given":"Bita","family":"Fakhri","sequence":"additional","affiliation":[{"name":"7Division of Hematology, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-3329","authenticated-orcid":false,"given":"Benoit","family":"Tessoulin","sequence":"additional","affiliation":[{"name":"8Haematology Department, University Hospital of Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6139-5486","authenticated-orcid":false,"given":"Shuo","family":"Ma","sequence":"additional","affiliation":[{"name":"9Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Jagadeesh","sequence":"additional","affiliation":[{"name":"10Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9592-0851","authenticated-orcid":false,"given":"Ewa","family":"Lech-Maranda","sequence":"additional","affiliation":[{"name":"11Institute of Hematology and Transfusion Medicine, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Coombs","sequence":"additional","affiliation":[{"name":"12Division of Hematology\/Oncology, University of California Irvine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6836-2364","authenticated-orcid":false,"given":"Manish R.","family":"Patel","sequence":"additional","affiliation":[{"name":"13Florida Cancer Specialists, Sarasota, FL"},{"name":"14Sarah Cannon Research Institute, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna M.","family":"Rhodes","sequence":"additional","affiliation":[{"name":"15Rutgers Cancer Institute of New Jersey, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-1510","authenticated-orcid":false,"given":"Chaitra","family":"Ujjani","sequence":"additional","affiliation":[{"name":"16Division of Hematology and Oncology, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"17The University of Kansas Cancer Center, Kansas City, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7988-1565","authenticated-orcid":false,"given":"Chan Y.","family":"Cheah","sequence":"additional","affiliation":[{"name":"18Linear Clinical Research and Sir Charles Gairdner Hospital, Nedlands, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-0769","authenticated-orcid":false,"given":"Talha","family":"Munir","sequence":"additional","affiliation":[{"name":"19Department of Haematology, St James's University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lewis","sequence":"additional","affiliation":[{"name":"20University Hospitals Plymouth NHS, Plymouth, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0844-0989","authenticated-orcid":false,"given":"Lydia","family":"Scarf\u00f2","sequence":"additional","affiliation":[{"name":"21Universit\u00e0 Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9749","authenticated-orcid":false,"given":"Toby A.","family":"Eyre","sequence":"additional","affiliation":[{"name":"22Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1720-9295","authenticated-orcid":false,"given":"Alvaro","family":"Alencar","sequence":"additional","affiliation":[{"name":"23University of Miami Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-6481","authenticated-orcid":false,"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"24Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1403-6883","authenticated-orcid":false,"given":"Andrew D.","family":"Zelenetz","sequence":"additional","affiliation":[{"name":"25Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald E.","family":"Tsai","sequence":"additional","affiliation":[{"name":"26Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[{"name":"26Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Bian","sequence":"additional","affiliation":[{"name":"26Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Abada","sequence":"additional","affiliation":[{"name":"26Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Balbas","sequence":"additional","affiliation":[{"name":"26Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"27Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"},{"name":"28Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"1","key":"2026041408011915900_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.2021.278755","article-title":"Marginal zone lymphoma: present status and future perspectives","volume":"107","author":"Cheah","year":"2022","journal-title":"Haematologica"},{"key":"2026041408011915900_bib2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.12688\/f1000research.13826.1","article-title":"Recent advances in understanding the biology of marginal zone lymphoma","volume":"7","author":"Bertoni","year":"2018","journal-title":"F1000Res"},{"issue":"12","key":"2026041408011915900_bib3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11864-019-0687-5","article-title":"Marginal zone lymphoma: state-of-the-art treatment","volume":"20","author":"Sindel","year":"2019","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"2026041408011915900_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"2026041408011915900_bib5","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/hematology.2022000362","article-title":"Management of marginal zone lymphomas","volume":"2022","author":"Merli","year":"2022","journal-title":"Hematology"},{"issue":"17","key":"2026041408011915900_bib6","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J Clin Oncol"},{"issue":"17","key":"2026041408011915900_bib7","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2015-12-624296","article-title":"Optimizing therapy for nodal marginal zone lymphoma","volume":"127","author":"Thieblemont","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2026041408011915900_bib8","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2018-02-833608","article-title":"Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance","volume":"132","author":"Kalpadakis","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2026041408011915900_bib9","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1097\/HS9.0000000000000699","article-title":"Immunochemotherapy and maintenance with obinutuzumab or rituximab in patients with previously untreated marginal zone lymphoma in the randomized GALLIUM trial","volume":"6","author":"Herold","year":"2022","journal-title":"Hemasphere"},{"issue":"1","key":"2026041408011915900_bib10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/hematology.2020000157","article-title":"How do we sequence therapy for marginal zone lymphomas?","volume":"2020","author":"Broccoli","year":"2020","journal-title":"Hematology"},{"key":"2026041408011915900_bib11","doi-asserted-by":"crossref","first-page":"1327309","DOI":"10.3389\/fonc.2024.1327309","article-title":"Advances in the treatment of relapsed\/refractory marginal zone lymphoma","volume":"14","author":"Wang","year":"2024","journal-title":"Front Oncol"},{"issue":"1","key":"2026041408011915900_bib12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"2026041408011915900_bib13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"14","key":"2026041408011915900_bib14","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"issue":"23","key":"2026041408011915900_bib15","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1158\/1078-0432.CCR-21-1704","article-title":"The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed\/refractory marginal zone lymphoma","volume":"27","author":"Opat","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026041408011915900_bib16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.18368","article-title":"A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma","volume":"199","author":"Strati","year":"2022","journal-title":"Br J Haematol"},{"issue":"16","key":"2026041408011915900_bib17","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"issue":"14","key":"2026041408011915900_bib18","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1182\/bloodadvances.2022009412","article-title":"Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma","volume":"7","author":"Tatarczuch","year":"2023","journal-title":"Blood Adv"},{"issue":"22","key":"2026041408011915900_bib19","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2026041408011915900_bib20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/bloodadvances.2022008634","article-title":"Postibrutinib relapse outcomes for patients with marginal zone lymphoma","volume":"7","author":"Epperla","year":"2023","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026041408011915900_bib21","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood-2024-194627","article-title":"5-year follow-up analysis from ZUMA-5: a phase 2 trial of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"144","author":"Neelapu","year":"2024","journal-title":"Blood"},{"issue":"10277","key":"2026041408011915900_bib22","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"24","key":"2026041408011915900_bib23","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1200\/JCO.23.00562","article-title":"Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026041408011915900_bib24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med"},{"key":"2026041408011915900_bib25","author":"Food and Drug Administration","year":"2023"},{"key":"2026041408011915900_bib26","author":"Food and Drug Administration","year":"2023"},{"key":"2026041408011915900_bib27","author":"European Medicines Agency","year":"2023"},{"issue":"27","key":"2026041408011915900_bib28","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12.5","key":"2026041408011915900_bib29","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.6004\/jnccn.2020.5035","article-title":"Challenges and opportunities in marginal zone lymphoma: implications of biology on treatment","volume":"18","author":"Smith","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"suppl 1","key":"2026041408011915900_bib30","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1182\/blood-2023-182347","article-title":"Efficacy and safety of ibrutinib in relapsed or refractory marginal zone lymphomas: the \u201creal world\u201d Italian experience","volume":"142","author":"Merli","year":"2023","journal-title":"Blood"},{"key":"2026041408011915900_bib31","unstructured":"Referenced with permission from the NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) for the NCCN clinical practice guidelines in oncology for B-cell lymphomas version 2.2025. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed 8 May 2025. https:\/\/www.nccn.org\/guidelines\/recently-published-guidelines."},{"issue":"1","key":"2026041408011915900_bib32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-022-01316-1","article-title":"Predictive factors and outcomes for ibrutinib in relapsed\/refractory marginal zone lymphoma: a multicenter cohort study","volume":"15","author":"Epperla","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2026041408011915900_bib33","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/bloodadvances.2018029058","article-title":"Resistance mechanism for ibrutinib in marginal zone lymphoma","volume":"3","author":"Epperla","year":"2019","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2441\/2512261\/blooda_adv-2025-017489-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2441\/2512261\/blooda_adv-2025-017489-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:01:29Z","timestamp":1776168089000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/7\/2441\/566043\/Pirtobrutinib-a-highly-selective-noncovalent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017489","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,14]]},"published":{"date-parts":[[2026,4,2]]}}}